Seladelpar sodium salt
| 中文名称 | Seladelpar sodium salt |
|---|---|
| 中文同义词 | 化合物 T12876 |
| 英文名称 | Seladelpar sodium salt |
| 英文同义词 | Seladelpar sodium salt |
| CAS号 | |
| 分子式 | C??H??F?NaO?S |
| 分子量 | 0 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | Mol File |
| 结构式 |
Seladelpar sodium salt 性质
| 形态 | 固体 |
|---|---|
| 颜色 | 白色至米白色 |
|
PPAR-δ 2 nM (EC 50 ) |
MBX-8025 is an orally active, potent (EC 50 =2 nM), and specific (750-fold and 2500-fold compared with PPARα or PPARγ receptors, respectively) PPARδ agonist being developed as a lipid-altering agent.
In atherogenic diet-fed Wt mice, administration of Seladelpar sodium salt reduces body weight by ~18% (P<0.05). In contrast, Seladelpar sodium salt produces minimal effect on body weight in atherogenic diet-fed foz/foz mice. Seladelpar sodium salt lowers serum alanine aminotransferase (ALT) levels in foz/foz mice (P<0.05) and similarly (but not significantly) in Wt mice. Seladelpar sodium salt normalizes serum cholesterol and decreases triglycerides in both genotypes (P<0.05). Seladelpar sodium salt abolishes hepatocyte ballooning (P<0.05) and decreases the nonalcoholic fatty liver disease (NAFLD) activity score by ~50%. Seladelpar sodium salt also significantly reduces sirius red-positive areas in foz/foz mice (P<0.05).